Advertisement

Clinical Drug Investigation

, Volume 28, Issue 5, pp 327–332 | Cite as

Retrospective Analysis of Rosiglitazone and Macular Oedema in Patients with Type 2 Diabetes Mellitus

  • Patrizio Tatti
  • Franco Arrigoni
  • Adriano Longobardi
  • Flavia Costanza
  • Patrizia Di Blasi
  • Domenico Merante
Original Research Article

Abstract

Background:

Macular oedema tends to be a more rapid complication of diabetic retinopathy and represents the major cause of blindness. Among subjects with type 2 diabetes mellitus, it can be found in 15% of those who use insulin and 4% of those who do not. Use of thiazolidinediones (glitazones) has recently been associated with some cases of macular oedema.

Methods:

We recalled 102 diabetic subjects treated with rosiglitazone to our diabetes centre in order to evaluate a possible association of this drug with macular oedema. Of these 102 subjects, we evaluated all 76 who provided written informed consent to participate in the analysis. All of these underwent a battery of four diagnostic tests: (1) visual acuity, (2) Amsler visual field test, (3) Ishihara colour recognition test, and (4) retinal fundus photography. All retinal photographs were examined by two experienced ophthalmologists.

Results:

The most noticeable result was that most subjects (80%) had satisfactory visual acuity. The Ishihara test chart showed that three subjects were colour blind, but this abnormality was already known. On the Amsler test, one subject had a positive result consisting of visual distortion of a series of straight lines. In the retinal photos, two expert ophthalmologists independently identified one case of‘paramacular oedema’ in a subject with diabetes of long duration with a proliferative retinopathy. The patient developed bilateral macular oedema during treatment with rosiglitazone 8 mg/day. The patient had been diagnosed with diabetes at the age of 45 years and after a period of 6 years taking oral antihyperglycaemic agents had been switched to insulin, up to four injections per day (total 60-70 IU/day),for the next 15 years. In 2000 a routine examination demonstrated the presence of sustained hypertension and the patient was started on an ACE inhibitor. A computerized test for autonomic neuropathy demonstrated abnormal deep breathing and lying-to-standing responses. Treatment with rosiglitazone was interrupted and the subject underwent a series of retinal photocoagulations for proliferative retinopathy. Two months after rosiglitazone therapy had been discontinued, the visual acuity of the patient reversed to baseline values.

Conclusion:

The study shows that rosiglitazone was not linked to formation of macular oedema, with the exception of one case of bilateral and clinically reversible paramacular oedema, where rosiglitazone was given in co-administration with a long-term insulin treatment regimen in a subject with pre-existing diabetic retinopathy. This patient had a long duration of diabetes and had also been hypertensive since 2000.

Keywords

Visual Acuity Diabetic Retinopathy Rosiglitazone Pioglitazone Macular Oedema 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This study was independently funded by the Diabetes Unit of the Marino Hospial, Rome, Italy. It was conducted as part of a routine pharmacovigilance survey of all utilized marketed products prescribed by the same Diabetes Unit. At the time the study was conducted Dr Di Blasi and Dr Merante were both employees of GlaxoSmithKline SpA; the other authors have no conflicts of interest that are directly relevant to the content of this study.

References

  1. 1.
    Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106–8PubMedCrossRefGoogle Scholar
  2. 2.
    Goldstein BJ. Differentiating members of the thiazolidinedione class: a focus on efficacy. Diabetes Metabol Res Rev 2002; 18: S16–22CrossRefGoogle Scholar
  3. 3.
    Wooltorton E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ 2002; 166(2): 219PubMedGoogle Scholar
  4. 4.
    Scheen A. Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf 2004; 27(12): 841–56PubMedCrossRefGoogle Scholar
  5. 5.
    Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004 Jan; 27(1): 256–63PubMedCrossRefGoogle Scholar
  6. 6.
    Canadian Diabetes Association. 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27Suppl. 2: Sl–152Google Scholar
  7. 7.
    Harby K. Glitazone use may be associated with macular edema in diabetes [online]. Available from URL: http://www.med-scape.com/viewarticle/464732. [Accessed 2004 July 7]
  8. 8.
    Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol 2005; 123: 1273–5PubMedCrossRefGoogle Scholar
  9. 9.
    Kendall C, Wooltorton E. Rosiglitazone (Avandia) and macular edema. CMAJ 2006 Feb 28; 174(5): 623PubMedCrossRefGoogle Scholar
  10. 10.
    Porta M, Bandello F. Diabetic retinopathy: a clinical update. Diabetologia 2002; 45: 1617–34PubMedCrossRefGoogle Scholar
  11. 11.
    European Medicines Agency press release. Committee for Medicinal Products for Human Use: 2005 Dec 11–14 [online]. Available from URL: http://www.emea.eu.int/pdfs/human/press/pr/42148405en.pdf [Accessed 2008 Apr 8]
  12. 12.
    Nota informativa importante su Rosiglitazone from AIFA (2006 Jan 19) [online]. Available from URL: http://www.aifa.gov.it/wscs_render_attachment_by_id/111.6043.11380328864053963.pdf?id=l11.6050.1138032886728 [Accessed 2008 Apr 8]
  13. 13.
    Cavanagh P. The Ishihara test and defects of colour vision. Br J Physiol Opt 1956 Jan; 13(1): 25–38PubMedGoogle Scholar
  14. 14.
    Wolfe KA, Sadun AA. Threshold Amsler grid testing in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 1991; 229(3): 219–23PubMedCrossRefGoogle Scholar
  15. 15.
    Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26: 2653–64PubMedCrossRefGoogle Scholar
  16. 16.
    Avandia. Summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?.DocumentID = 3200 [Accessed 2008 Apr 8]

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Patrizio Tatti
    • 1
  • Franco Arrigoni
    • 2
  • Adriano Longobardi
    • 2
  • Flavia Costanza
    • 1
  • Patrizia Di Blasi
    • 3
  • Domenico Merante
    • 3
  1. 1.Diabetes CenterMarino HospitalRomeItaly
  2. 2.Ophthalmological DepartmentMarino HospitalRomeItaly
  3. 3.Medical DepartmentGlaxoSmithKline SpAVeronaItaly

Personalised recommendations